Literature DB >> 8584236

Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model.

Y W Lee1, S R Chaplan, T L Yaksh.   

Abstract

The effects of intraperitoneal (I.P.), intracerebroventricular (ICV) and intrathecal (IT) opiates were studied in the rat neuropathic pain model of Kim and Chung. Dose dependent reduction of allodynia was observed after I.P. and ICV morphine, but not after IT morphine, IT or ICV c[D-pen2 D-pen5]enkephalin (DPDPE) (delta agonist), or IT or ICV U50488H (kappa agonist). The effects of ICV morphine were blocked by I.P. naloxone, but not by IT methysergide, phentolamine or 8-sulfophenyltheophylline. Catalepsy (immobility) was observed after IT, ICV and IT morphine but this was not reliably associated with a reduction of allodynia. I.P. and ICV morphine may thus reduce tactile allodynia via supraspinal, but not spinal, mu opioid receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8584236     DOI: 10.1016/0304-3940(95)12034-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  21 in total

1.  Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.

Authors:  T M Largent-Milnes; T Yamamoto; P Nair; J W Moulton; V J Hruby; J Lai; F Porreca; T W Vanderah
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Endogenous opioid mechanisms partially mediate P2X3/P2X2/3-related antinociception in rat models of inflammatory and chemogenic pain but not neuropathic pain.

Authors:  Steve McGaraughty; Prisca Honore; Carol T Wismer; Joseph Mikusa; Chang Z Zhu; Heath A McDonald; Bruce Bianchi; Connie R Faltynek; Michael F Jarvis
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

Review 3.  Pharmacologic treatment of neuropathic pain.

Authors:  M S Wallace
Journal:  Curr Pain Headache Rep       Date:  2001-04

4.  Nerve injury-induced tactile allodynia is present in the absence of FOS labeling in retrogradely labeled post-synaptic dorsal column neurons.

Authors:  En-Tan Zhang; Michael H Ossipov; Dong-Qin Zhang; Josephine Lai; Frank Porreca
Journal:  Pain       Date:  2006-12-06       Impact factor: 6.961

5.  Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids.

Authors:  Victoria C J Wallace; David F Cottrell; Peter J Brophy; Susan M Fleetwood-Walker
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

6.  Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation.

Authors:  I Obara; J Mika; M K-H Schafer; B Przewlocka
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

7.  Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats.

Authors:  Elizabeth J Rahn; Alexander M Zvonok; Ganesh A Thakur; Atmaram D Khanolkar; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2008-07-29       Impact factor: 4.030

Review 8.  Behavioral models of pain states evoked by physical injury to the peripheral nerve.

Authors:  Linda S Sorkin; Tony L Yaksh
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

9.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.

Authors:  Tally M Largent-Milnes; Wenhong Guo; Hoau-Yan Wang; Lindsay H Burns; Todd W Vanderah
Journal:  J Pain       Date:  2008-05-12       Impact factor: 5.820

10.  Pharmacological Modulation of Endogenous Opioid Activity to Attenuate Neuropathic Pain in Rats.

Authors:  Nai-Jiang Liu; Emiliya M Storman; Alan R Gintzler
Journal:  J Pain       Date:  2018-10-23       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.